
A MESSAGE FROM OUR ADVISORY BOARD



I'm Beth Garner, Chief Scientific Officer, U.S. at Ferring Pharmaceuticals Inc. – I'm an OB/GYN by training and a women's health industry leader by design. Women's health is the category nearest and dearest to my heart and one which I've focused on throughout my life and career. I'm privileged to keep learning, growing and solving critical problems for women and families through my work at Ferring and through the meaningful connections with fascinating individuals and companies like you, who are leading the charge in women's health innovation.

FERRING

PHARMACEUTICALS

At Ferring, our goal in reproductive medicine is to enable more people to start or grow their families and support them (and the physicians who care for them) as they navigate their own unique fertility journeys. We do this in many ways, including by providing innovative therapies and offering educational programs and resources. An exciting new focus area for us is in male factor infertility – an area with a tremendously large unmet need where current protocols still place the burden of treatment on the female partner. We want to change that and are committed to paving the way forward with this research.

Ferring is in a unique position as one of the few companies that continues to invest in researching solutions for unmet needs in reproductive medicine and maternal health. We are proud of this, but we can't do it alone.

As we know, innovations in reproductive medicine and maternal health are keys to greater economic prosperity and well-being of families worldwide. In February, I had the opportunity to speak at the Reproductive Health Innovation Summit (RHIS) in Boston (and had the pleasure of seeing many of you there). I think you'll agree with me that it was inspiring – a stage and event for likeminded industry leaders, investors and start-ups to address critical challenges that have persisted for decades. The packed seats and energetic conversations I had and continue to

A MESSAGE FROM OUR ADVISORY BOARD

have in the months following the event, give me hope and optimism for the future. The more minds we have working to solve these problems, the better.

I was deeply inspired by my experience at RHIS and motivated to seek out the exciting technologies and concepts that are emerging. For example:

- I'm hopeful about the potential for innovations in AI that may lead to more precise diagnoses that ultimately improve outcomes.
- I'm also curious about new technologies that will help address the enormous time burden that fertility treatments can place on individuals and couples, such as daily monitoring appointments and bloodwork in the clinic, and frequent ultrasounds.

More than individual ideas, the opportunity to come together with others who also would like to advance reproductive health will be the way we continue to move this category forward. And if the momentum continues—as I know it will—the relationships and collaboration that we are fostering between industry, investors and innovators will undoubtedly improve the lives of women and their families.

Looking forward to working together!

Beth
